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ABSTRACT 
Oxidative stress appears to have an important role in glucocorticoid insensitivity, as a crucial 
problem in asthma therapy. We studied the preventive effect of antioxidant N-acetylcysteine 
(NAC) on the airway hyper-responsiveness (AHR) and the accumulation of inflammatory 
cells in the airways in an animal model of steroid resistant acute exacerbation of asthma. Sys-
temically sensitized Balb/C mice were exposed to Ovalbumin aerosol on days 13, 14, 15 and 
16, followed by intratracheal lipopolysaccharide (LPS) to induce acute exacerbation. NAC 
(intraperitoneal, 320 mg/kg 30 min before and 12 hours after each challenge) reduced hyper-
responsiveness with/out dexamethasone. LPS application caused neutrophilia in bronchoalve-
olar lavage fluid (BALF) and eosinophil count was higher than respective control in BALF as 
well as neutrophils after dexamethasone treatment. NAC significantly decreased neutrophil 
and eosinophil count in BALF as well as inflammatory cytokines (IL-13 and IL-5).We con-
cluded that addition of NAC to asthma therapy has beneficial preventive effects in an animal 
model of steroid resistant acute exacerbation of asthma. 
 
Keywords: steroid resistant asthma, acute exacerbation, N-acetylcysteine, eosinophil, neutro-
phil 
 
 
 
INTRODUCTION 
Asthma is a chronic disorder which is 
associated with inflammation and immune 
cell infiltration to the airways (Song et al., 
2009). Constant presence of inflammatory 
mediators and immune cells in airways re-
sult in airway hyper-responsiveness (AHR) 
which is clinically pictured as breathless-
ness, coughing and wheezing (Li et al., 
2010). Among asthma medications gluco-
corticoids are the most effective and first 
line therapeutics in reducing inflammation. 
However, some patients with severe asthma 
experience resistance to steroids even at 
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high doses of glucocorticoids. Steroid in-
sensitivity is a crucial problem in asthma 
therapy and adds cost burden to the health 
system as well as patient discomfort 
(Barnes, 2010; Marwick et al., 2010). In 
contrast to mild/moderate asthma, the major 
characteristic of severe asthma is neutro-
philia and an elevation in oxidative stress in 
the lung (Marwick et al., 2010). 
The oxidative stress may have both exo-
genous and endogenous sources and its in-
crease in the lung is a key element in devel-
opment of glucocorticoid resistance in res-
piratory diseases (Chung and Adcock, 
2008; Ciencewicki et al., 2008). As an en-
dogenous source, pro-inflammatory cells 
such as macrophages and neutrophils can 
produce reactive oxygen/nitrogen species 
(Marwick et al., 2010). Comparing to other 
cell types, neutrophils and their resulting 
inflammation is irresponsive to glucocorti-
coids (Marwick et al., 2009). As oxidative 
stress plays an important role in glucocorti-
coid insensitivity, targeting it with antioxi-
dants seems to be a good choice.  
N-acetylcysteine (NAC) has shown a 
therapeutic effect in oxidative stress de-
crease in some respiratory diseases (Cai et 
al., 2009). Therefore, there is an open win-
dow for NAC’s likely effect on glucocorti-
coid sensitivity in severe neutrophilic asth-
ma. In this study we investigated the pre-
dictive effect of NAC, as an antioxidant, in 
an animal model of steroid resistant acute 
exacerbation of asthma. 
 
MATERIALS AND METHODS 
Animals 
Male specific pathogen free Balb/C 
mice, 6-8 weeks, were purchased from an-
imal services unit, University of Newcastle, 
NSW. Animals were housed in individual 
cages. Animals were kept in an approved 
condition under controlled temperature and 
humidity and received food and water ad 
libitum with 12 hour light/dark cycle. All 
protocols for experiments and procedures 
were approved by the Animal Care and Use 
Committee of the University of Newcastle. 
 
Experimental model 
Animals were sensitized intra-peri-
toneally (i.p.) by injection of 50 μg of 
chicken egg ovalbumin (OVA) (Grade V, 
≥ 98 % pure; Sigma, St Louis, MO) ad-
sorbed to 1 mg of Alhydrogel (Reheis Inc., 
Berkley Heights, NJ, USA) suspended in 
total volume of 200 µL of 0.9 % sterile sa-
line on day 0 before the commencement of 
aerosol challenge. Non-sensitized animals 
were injected the same suspension without 
OVA. All groups were exposed to aeroso-
lized OVA (10 mg/ml OVA dissolved in 
0.9 % sterile saline for 30 min) on days 13, 
14, 15 and 16 using an ultrasonic nebulizer 
in a whole-body inhalation exposure cham-
ber. Intratracheal (i.t.) lipopolysaccharide 
(LPS) (100 ng/mouse) was applied to sensi-
tized group and saline to non-sensitized 
group on day 22.  
 
Drug treatment 
N-acetylcysteine (NAC) (Sigma-
Aldrich) was dissolved in phosphate buffer 
saline (PBS) and was neutralized to the pH 
7.4 with bicarbonate (1 mol/L) to the final 
volume of 200 µL (Máximo Cardoso et al., 
2006). Freshly made NAC solution was in-
jected i.p. (320 mg/kg) every 12 hours dur-
ing aerosol days starting 30 min before the 
first challenge and ending 12 hours after the 
last challenge. At 24 and 2 hours before the 
LPS challenge, animals received either 
dexamethasone (Dex) (1 mg/kg; Sigma-
Aldrich), or vehicle alone by i.p. injection. 
Moreover, NAC was injected to the animals 
30 min before and 12 hours after LPS chal-
lenge. 
 
Experimental groups 
There were 8 groups in this study and 
groups included 8 animals each. Groups 
were as follow: 1) PBS/OVA/Veh/Veh 
(non-sensitized, NAC vehicle, Dex vehi-
cle), 2) PBS/OVA/NAC/Veh (non-sensiti-
zed, NAC, Dex vehicle), 3) PBS/OVA/ 
Veh/Dex (non-sensitized, NAC vehicle, 
Dex), 4) PBS/OVA/NAC/Dex (non-sensi-
tized, NAC, Dex), 5) OVA/OVA/Veh/ Veh 
(sensitized, NAC vehicle, Dex vehicle), 6) 
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OVA/OVA/NAC/Veh (sensitized, NAC, 
Dex vehicle), 7) OVA/OVA/Veh/ Dex 
(sensitized, NAC vehicle, Dex), 8) OVA/ 
OVA/NAC/Dex (sensitized, NAC, Dex). 
Animals were sacrificed on day 23 for 
AHR and inflammatory cell assessment in 
broncho-alveolar lavage fluid (BALF).  
 
Measurement of airway hyper-
responsiveness 
Airway responses to increasing doses of 
β-methacholine (Mch) (Sigma-Aldrich) 
were determined 24 hours after LPS chal-
lenge by means of Flexivent apparatus 
(Scireq; Montreal, Quebec, Canada). Mice 
were anesthetized with a combination of 
Ketamine-Xylazine. Concentrations for 
Ketamine (Parnell, Alexandria, New South 
Wales, Australia) and Xylazine (Troy La-
boratories, Smithfield, New South Wales, 
Australia) were 40 mg/ml and 2 mg/ml, re-
spectively. Animals were tracheostomized 
and a tracheal cannula was inserted in tra-
chea and mice attached to the machine. A 
supplementary dose of anesthetic mixture 
was injected after ventilation started at the 
rate of 450 breaths/min with tidal volume of 
8 ml/kg and positive end-expiratory pres-
sure of 2 cm H2O. After mice were settled 
and baseline was recorded, Mch challenge 
was performed starting with aerosolized 
saline as a first dose followed by rising 
concentrations of freshly prepared Mch 
(0.1, 0.3, 1, 3, 10 and 30 mg/ml; Sigma-
Aldrich). Each dose was nebulized through 
the ultrasonic nebulizer provided by Scireq 
to be installed on the inspiration pathway of 
the machine. If coefficient of determination 
(COD) was less than 95 %, the record was 
excluded. Rn corresponds to the resistance 
of central airways. AHR was described as a 
significant change in Rn comparing to con-
trol group. Data is shown as percentage in-
crease in Rn over saline control (Li et al., 
2010; Ito et al., 2008).  
 
Broncho-alveolar lavage (BAL) 
After performing Flexivent, mice were 
sacrificed with sodium pentobarbitone 
(100 mg/kg) (Lethabarb, Virbac, Australia) 
and the broncho-alveolar lavage was per-
formed with 2 × 0.9 ml Hank's Buffered 
Salt Solution (HBSS). BALF from each an-
imal was collected in a plastic tube sepa-
rately and kept on ice. All tubes then centri-
fuged (3000 g) at 4 °C for 5 min. Cell pel-
lets were re-suspended in 50 µL of RBC 
lysis buffer and centrifuged again after 5 
min. Pellets re-suspended in 200 µL 
HBSSC and cell viability was carried out 
with Trypan blue. Then cell suspensions 
were cytospined (Cytospin 4, Thermo 
Shandon, NC, USA). After 24 hours, slides 
were stained with May-Grünwald/Giemsa 
and cover slipped; then counted on at least 
300 cells (Ito et al., 2008). Differential cell 
counts were compared to the respective 
control group. 
 
RT-QPCR 
Total RNA extracted from the whole 
lung samples, stored in -80 °C, and reverse 
transcription were carried out for samples 
using TRIzol RNA isolation buffer follow-
ing the manufacturer’s instructions (Invi-
trogen). cDNA synthesis was performed 
using oligo(dT)-primed reverse transcrip-
tase reactions consuming 0.5 mg RNA from 
each sample. Transcription levels of IL-13 
and IL-5 genes, and HPRT, as a housekeep-
ing gene, were quantified. IL-13 forward: 
"5'-AGCTGCAACATCACACAAGACC" 
and reverse "5'-TGGGCTACTTCGA 
TTTTGGTATCG", IL-5 forward "5'-TGTT 
GACAAGCAATGAGACGATGA" and 
reverse "5'-AATAGCATTTCCACAGTA 
CCCCCA" and HPRT forward "AGGCCA 
GACTTTGTTGGATTTGAA" and reverse 
"CAACTTGCGCTCATCTTAGGCTTT" 
primers (Sigma, UK) were used for real-
time PCR. Mastercycler ep realplex and 
cyber green were used to quantify gene 
transcripts and to detect changes in am-
plicon levels with each sequential amplifi-
cation cycle. The levels of mRNA from 
groups were normalized to HPRT. 
 
Statistical analysis 
Data are presented as mean ± SD. Sta-
tistical analysis were performed by one way 
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analysis of variance (ANOVA) and two 
way ANOVA followed by Bonferroni test 
for post-hoc analysis using GraphPad Prism 
5 (GraphPad Software Inc, San Diego, CA, 
USA). Significance was defined at the level 
of p<0.05. 
 
RESULTS 
NAC reduces hyper-responsiveness 
with/out dexamethasone 
OVA sensitized, OVA aerosolized mice 
showed AHR (Figure 1) and increase in 
airway inflammation comparing to respec-
tive control group. Significant increase in 
airway resistance (Rn), tissue damping (G) 
and tissue elastance (H) were observed after 
LPS challenge (Figure 1). OVA aerosol 
treated mice exhibited higher AHR rate in 
dose 30mg/ml Mch comparing to respective 
control group which was persistent after 
dexamethasone application (Figure 1). 
However, NAC could decrease Rn, G and H 
with or without application of Dex in OVA 
treated mice (Figure 2). 
 
NAC decreases airway inflammation by 
affecting cell recruitment 
Asthma exacerbation resulted in total 
cell number increase in airways which was 
decreased significantly by NAC application 
(Figure 3a). LPS treatment caused neutro-
philia in airways which was resistant to 
dexamethasone. NAC significantly de-
creased neutrophil count in BALF (p<0.05) 
(Figure 3b). Total number of lymphocytes 
was increased in BALF after LPS induc-
tion. However, this increase was not re-
sistant to Dex. NAC decreased the lympho-
cyte recruitment to the lung without Dex 
presence (Figure 3c). Macrophages were 
recruited to the lung after LPS challenge 
followed by Dex injection which was de-
creased significantly to respective control 
levels by NAC application (Figure 3d). Eo-
sinophil count was higher than respective 
control in BALF after LPS induction and 
Dex treatment. However, NAC decreased 
eosinophilia in this group (Figure 3e). 
 
Figure 1: Asthma induction contributes in AHR 
which is resistant to Dex. AHR was studied us-
ing Flexivent apparatus and increasing doses of 
Mch. Airway resistance (Rn) (a), Tissue damp-
ing (b) and tissue elastance (c) were signifi-
cantly increased in asthma exacerbation. Dex 
application did not reduce the AHR. *p<0.05, as 
compared to respective controls 
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Figure 2: NAC reduces AHR in asthma exac-
erbation with/out Dex. AHR was studied using 
Flexivent apparatus and increasing doses of 
Mch. Airway resistance (Rn) (a), Tissue damp-
ing (b) and tissue elastance (c) were decreased 
to the control levels in asthma exacerbation 
with NAC application (320 mg/kg every 12 
hours). *p<0.05, as compared to respective 
controls 
 
 
 
Figure 3a-c: Inducing LPS contributes to neu-
trophilia in airways which is resistant to Dex. 
NAC application prevented neutrophilia (a). 
Number of lymphocytes was increased with 
asthma induction which was not resistant to 
Dex. NAC prevented lymphocyte accumulation 
in airways (b). The number of macrophages 
and eosinophils increased with asthma induc-
tion and Dex application but not with asthma 
induction alone (c and d). 
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Figure 3d-e (legend see above): *p<0.05, as 
compared to respective control; #p<0.05, as 
compared to respective asthma 
 
 
NAC decreases inflammation by regulat-
ing gene expression  
Gene expression was quantified using 
Cyber green and real time PCR machine 
and the level of amplicons were normalized 
to HPRT gene expression. Asthma exacer-
bation induction increased the IL-13 and 
IL-5 gene expression levels in the lung 
which was resistant to Dex. As it is shown 
in Figure 4, IL-13 gene expression in-
creased dramatically after asthma exacerba-
tion and Dex application did not affect the 
increase in IL-13 gene expression. Howev-
er, NAC decreased IL-13 expression level 
to control levels even in absence of Dex. 
IL-5 gene expression surged in asthma ex-
acerbation. This surge was intensely higher 
in Dex treated asthma group. NAC applica-
tion diminished the IL-5 level with or with-
out Dex use (Figure 5). 
 
Figure 4: IL-13 expression is fed by asthma 
induction. Induction of asthma resulted in a 
dramatic increase in IL-13 gene expression 
which was resistant to steroid therapy. Applica-
tion of NAC (320 mg/kg) every 12 hours starting 
30 min before the first OVA challenge and fin-
ishing 12 hours after the last challenge pre-
vented the expression of this chemokine and 
kept it to the control levels. Data are presented 
as means ± S.E. (error bars), n = 8; *p<0.05 for 
the comparisons to the respective control and 
#p<0.05 for the comparisons to the respective 
asthma group 
 
Figure 5: IL-5 expression is increased by 
asthma induction. Induction of asthma resulted 
in an increase in IL-5 gene expression in asth-
ma group while this rise was drastic after Dex 
application. Application of NAC (320 mg/kg) 
every 12 hours starting 30 min before the first 
OVA challenge and finishing 12 hours after the 
last challenge prevented the expression of this 
chemokine and kept it to the control levels. Da-
ta are presented as means ± S.E. (error bars), 
n = 8; *p<0.05 and ***p<0.001 for the compari-
sons to the respective control and #p<0.05 for 
the comparisons to the respective asthma 
group 
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DISCUSSION 
Applied model led to steroid resistant 
acute exacerbation of asthma in mice which 
resulted in AHR, increased airway re-
sistance, tissue damping and tissue elas-
tance. Also, total cell number, especially 
neutrophils, elevated in airways after LPS 
induction. NAC application decreased AHR 
and cell recruitment to the lung. 
Intraperitoneal injection of OVA sensi-
tizes mice and activates immune cells in 
airways (Ito et al., 2008). OVA aerosol in-
creases the cell activation, migration and 
cytokine secretion. IL-13 and IL-5, released 
from Th2 cells, increase eosinophils by 
stimulating bone marrow to produce more 
progenitor cells and alter their differentia-
tion to eosinophils and affect their migra-
tion to the lung (Larché, 2006). Moreover, 
these cytokines increase airway hyper-
responsiveness which is the clinical picture 
of asthma. Also, LPS presentation to the 
immune cells recruits neutrophils to the 
lung (Li et al., 2010). The results of this 
study show that intratracheal administration 
of LPS lead in neutrophilia in BALF (Fig-
ure 3b). Interestingly, Dex application in-
creased the number of eosinophils in BALF 
in steroid resistant asthmatic mice. Previous 
studies show excessive IL-5 secretion in 
presence of Dex helps in survival of eosino-
phils in the lung which is in accordance 
with our results (Bloom et al., 2004). 
High levels of oxidative stress are seen 
in patients with asthma and have been im-
plicated as a driving force behind the in-
flammatory response and corticosteroid in-
sensitivity in severe asthma (Kirkham and 
Rahman, 2006). Therefore, antioxidants 
that neutralize this oxidative stress in the 
airways might be of benefit and may restore 
corticosteroid sensitivity in asthmatic pa-
tients (Barnes, 2004). NAC is one of the 
most widely investigated antioxidants and 
reduces oxidant induced lung damage in a 
variety of experimental models (Cortijo et 
al., 2001; Leff et al., 1993; Bernareggi et 
al., 1999). However, the influence of NAC 
in experimental models of asthma remains 
uncertain. Blesa et al. reported that oral 
treatment with NAC produce anti-
hyperreactivity and anti-inflammatory ef-
fects in an animal model of allergic asthma 
(Blesa et al., 2002). On the other hand, Ali-
yali et al. demonstrated that addition of 
NAC to usual asthma medication has no 
significant effect in treatment of asthma ex-
acerbation (Aliyali et al., 2010). According 
to our knowledge, there is no study to in-
vestigate the impact of NAC in steroid re-
sistant asthma. We found that NAC was 
effective to reduce the AHR as well as the 
eosinophil and neutrophil counts in bron-
choalveolar lavage fluid in animal model of 
steroid resistant asthma. 
Oxidative stress activates p38 Mitogen 
Activated Protein Kinase (MAPK) in air-
way smooth muscle (Wuyts et al., 2003). 
p38 MAPK could lead to glucocorticoid 
insensitivity suggestively by interfering 
with the nuclear localization of glucocorti-
coid receptors (Irusen et al., 2002). In addi-
tion, p38 MAPK pathway provides cell pro-
liferation and differentiation in airway 
smooth muscle which is responsible for 
AHR. Beside antioxidant properties, NAC 
inhibits p38 MAPK pathway (Wuyts et al., 
2003). Hence, NAC could be of benefit in 
restoring steroid sensitivity and reducing 
the AHR in steroid resistant asthma. 
NAC increases GSH levels in cells and 
provides antioxidant defense to the cells. 
NAC affects immune responses and cyto-
kine production (Bengtsson et al., 2001). It 
is shown that oxidative burst of eosinophils 
is decreased by application of NAC on hu-
man eosinophils in vitro. Additionally, re-
active oxidative species production by neu-
trophils is reduced by NAC which is the 
result of GSH level elevation in these cells 
(Martinez-Losa et al., 2007). As it is shown 
in Figure 3, NAC reduces the eosinophil 
and neutrophil count in asthma groups 
comparing to the control groups which is in 
accordance with the results of other studies. 
The suggested mechanism is NAC inhibits 
NADPH oxidase translocation to neutro-
phils’ and eosinophils’ membrane (Marti-
nez-Losa et al., 2007). Besides its direct 
effect on eosinophils, NAC has effect on 
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immune cell attractive chemokines includ-
ing IL-5 (Bengtsson et al., 2001). As ex-
plained before, IL-5 is an eosinophil re-
cruiting cytokine (Shannon et al., 2008) and 
(Corren, 2012). Reducing IL-5 by NAC 
(Figure 5) decreases the number of eosino-
phils in lung (Figure 3e). IL-13 is another 
cytokine released from Th-2 cells and is a 
marker of asthma (Liang et al., 2012). NAC 
application reduced IL-13 (Figure 4) and 
AHR consequently. Studies have shown 
that NAC affected cytokine release from 
Th-2 cells which confirms our results 
(Bengtsson et al., 2001). 
In conclusion the results of this study 
indicated that addition of NAC to asthma 
therapy could be effective in increasing 
steroid sensitivity, reducing AHR and de-
creasing inflammatory cells in airways in 
an animal model of steroid resistant acute 
exacerbation of asthma.  
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